Detalhe da pesquisa
1.
Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry.
Breast Cancer Res Treat
; 201(2): 151-159, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37338729
2.
Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07).
Eur J Cancer Care (Engl)
; 29(4): e13253, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32578279
3.
Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis.
Oncologist
; 22(11): 1301-1308, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28701571
4.
Lower Breast Cancer Risk among Women following the World Cancer Research Fund and American Institute for Cancer Research Lifestyle Recommendations: EpiGEICAM Case-Control Study.
PLoS One
; 10(5): e0126096, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25978407
5.
Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients.
Blood
; 100(5): 1648-54, 2002 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12176884